Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689675 | PMC |
http://dx.doi.org/10.1016/j.xjtc.2021.03.005 | DOI Listing |
Pulm Ther
January 2025
MSc Program in Sleep Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient is referred to as overlap syndrome (OS). Patients with OS suffer more frequently from cardiovascular disease (CVD) and carry a higher risk of COPD-related exacerbations than patients with COPD alone, especially when OSA is left untreated. Based on recent evidence, triple therapy, namely inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-agonist (ICS-LABA-LAMA), is a treatment strategy in COPD patients with a history of exacerbations and/or CVD comorbidity.
View Article and Find Full Text PDFEur Respir J
December 2024
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
Eur Respir J
December 2024
Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Eur Respir J
December 2024
Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, USA.
Acta Paediatr
December 2024
Department of Pediatric and Adolescent Medicine, Division Neonatology and Pediatric Intensive Care, University Hospital, Jena, Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!